Answers are grounded in this paper and cite their sources.
Background/Objectives . Multiple organ dysfunction syndrome (MODS) is a critical condition frequently associated with sepsis and carries high mortality. Recent studies have highlighted the role of intestinal barrier disruption as a key contributor to systemic inflammation and organ failure. Identifying reliable biomarkers for early detection of gut injury may enhance risk stratification and improve outcomes in critically ill patients. Methods. In this prospective study, was analyzed serum levels of intestinal fatty acid-binding protein (I-FABP), regenerating islet-derived protein 3 alpha (REG3α), soluble CD14 subtype (sCD14-ST), lipopolysaccharide-binding protein (LBP), and zonulin in 227 patients with MODS and 100 controls without MODS. Organ dysfunction severity was assessed using APACHE II and SOFA scores. Statistical analyses included ROC curve analysis, Kruskal–Wallis tests, and logistic regression modeling. Results. Patients with MODS had significantly higher levels of all studied biomarkers compared to controls. I-FABP lev-els positively correlated with SOFA and APACHE II scores. ROC analysis identified an I-FABP threshold of 120.7 pg/mL as optimal for mortality risk stratification (sensitivity: 54.9%, specificity: 84.9%). Logistic regression confirmed I-FABP and APACHE II as independent predictors of mortality. A predictive model incorporating both variables demonstrated an overall accuracy of 84.3%, with 71.3% accuracy for deceased patients. An online calculator (LOP-MODS) was developed to facilitate bedside application. Conclusions. I-FABP is a promising early biomarker for predicting outcomes in patients with MODS. Its integration with clinical scoring systems like APACHE II may enhance prognostic accuracy and guide timely interventions in critical care set-tings. Registration of the Clinical Trial. This study was registered on the ClinicalTrials.gov website. The unique research registration identification number (UIN) is NCT06221293. Link: https://ichgcp.net/clinical-trials-registry/NCT06221293
No takes yet. Share an insight, caveat, or question.
Ogizbayeva et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: